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A B S T R A C T
Fine needle aspiration (FNA) cytology, together with imaging, has become a primary diagnostic modality for investi-
gation of pancreatic mass lesions, both cystic and solid. Advances in imaging techniques have enhanced our ability to
recognize and delineate pancreatic masses and to detect them earlier as smaller mass lesions. However, definitive man-
agement often cannot be based on clinical and radiological features alone. Despite the advances in the imaging tech-
niques, management options for patients are limited and a malignant diagnosis of solid lesions still carries a high mor-
tality rate. The importance of a cytopathologist in preoperative diagnosis, as a member of the multidisciplinary team, is
exemplified in the management of patients with neoplastic cysts. This is based on the pre-operative distinction of non-
-mucinous and mucinous cysts in general, and benign and malignant cysts in particular. A cytological diagnosis can be
obtained with minimally invasive techniques that utilize CT, US or EUS. Endoscopic Ultrasound guided FNA (EUS
FNA) is evolving as the diagnostic method of choice due to its ability to more accurately stage the patient during a single
procedure using EUS.
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Introduction
FNA remains the primary means of establishing a
pathological diagnosis pre-operatively. A core biopsy (CB)
of the pancreas is associated with a significant risk of
complications. The accuracy and utility of pre-operative
FNA is dependent on the quality of the sample as well as
the quality of the interpretation. Cytology interpretation
requires experience in pancreatic cytology using a multi-
modal approach that incorporates the clinical, radiologi-
cal and ancillary laboratory tests into the overall inter-
pretation of the specimen.
FNA Techniques
It is recognised widely that computerised tomography
(CT) is perhaps the most important single test used in
preoperative staging of pancreatic cancer and in assess-
ment of tumour resectability, and has been shown to be
superior to most other imaging modalities in accurately
predicting resectability and staging of pancreatic ade-
nocarcinoma1,2. With the advent of endoscopic ultra-
sound (EUS)3, transgastric or transduodenal FNA of
pancreatic masses has provided a useful investigation for
acquiring a sample to confirm the presence of pancreatic
cancer. EUS guided FNA, unlike percutaneous FNA, al-
lows biopsy of small (0.5 cm) lesions that are not evident
by conventional imaging studies4. The short needle path
decreases potential complications as well. EUS also si-
multaneously allows for accurate staging of pancreatic
malignancy by sampling suspicious peripancreatic nodes
and liver lesions. However, both techniques are robust
and the eventual choice is dependent on several factors
including availability of EUS and local expertise both in
obtaining and interpreting the FNA sample.
The EUS equipment consists of an image guidance
system and the echoendoscope that is placed into the
stomach or duodenum. Using the guidance of the high
frequency ultrasound transducer on the tip of the echo-
endoscope, a small 19–25 gauge needle is passed through
the wall of the gastrointestinal tract and into the pancre-
atic mass or cyst. Masses in the pancreatic head use a
transduodenal approach and those in the pancreatic
body and tail use a transgastric approach. Once in the le-
sion, the stylet is removed, suction is applied using a sy-
ringe, and the needle is moved back and forth within the
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lesion. If cystic, the cyst fluid is drained and submitted
for routine cytology, biochemical and possibly molecular
analysis. Any visible mural nodule or solid component
should be separately sampled. Obtaining formalin fixed
paraffin embedded tissue from needle rinses or core bi-
opsy (CB) provides additional morphological information
about the lesion and readily available tissue for ancillary
studies5.
Rapid on-Site Cytopathology Evaluation
Rapid on-site cytopathology evaluation (ROSE) has
been shown to improve the diagnostic yield of EUS-
-guided FNA6–8. Interpretation of selected smears by a
cytopathologist provides a sample from which adequate
interpretation can be made. In addition to the assess-
ment of the specimen adequacy, on site assessment al-
lows for appropriate triage of the specimen for ancillary
studies, such as flow cytometry and immunocytoche-
mistry9. Cyst fluids can produce direct smears if the fluid
is thick, but thin watery or bloody fluids are collected and
processed as cytospins by using routine stains and spe-
cial stains for mucin. Triage of cyst fluid for biochemical
analysis or molecular analysis can be performed either
by the sample taker (usually a gastroenterologist) or the
pathology lab.
The overall risk of complications from EUS-FNA is
relatively low at approximately 2%, with no severe or fa-
tal incidents reported10,11. The most common complica-
tions arising from FNA of the pancreas are hemorrhage
and pancreatitis12. With percutaneous FNA, tumour see-
ding along the cutaneous needle track is an extremely
rare event. Transperitoneal rather than needle track
spread may be of greater concern13. The biochemical
analysis of usually at least 1 mL of fresh, unfixed and un-
diluted fluid aspirated from cystic lesions of the pancreas
is very helpful in distinguishing cystic neoplasms from
pseudocysts, serous cysts from mucinous cysts, and be-
nign from malignant mucinous cystic neoplasms. CEA
has yielded the best results in discriminating between a
mucinous and non-mucinous cyst14. Amylase is the sec-
ond test that is very helpful in the pre-operative inter-
pretation of pancreatic cysts.
Diagnostic Accuracy of Pancreatic FNA
Diagnostic accuracy of pancreatic FNA depends pri-
marily on the nature of the lesion and the quality of the
material available but also on the experience of both, the
aspirator and the interpreter, and most importantly on
the communication between the radiological, surgical
and pathology teams. EUS FNA of the pancreas is a tech-
nically difficult procedure and yields aspirates that are
diagnostically challenging. Thus, the sensitivity is vari-
able, ranging from 60% to 100%15. Sensitivity of the pro-
cedure can increase overtime, reflecting increasing expe-
rience with this technique15. The specificity of diagnosis
in the setting of a solid pancreatic mass is greater than
90%. The adequacy and sensitivity rates are generally
higher when ROSE is available8. The inaccuracies of pan-
creatic FNA appear to be almost entirely due to false neg-
ative reports. The sensitivity for cystic neoplasms is
lower than that for solid neoplasms primarily due to the
sampling problems and low cellularity of most of the cys-
tic lesions16.
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TABLE 1




Serous cystadenoma Serous cystadenocarcinoma
Mucinous cystadenoma with
mild dysplasia
Mucinous cystic neoplasm with
moderate dysplasia
Mucinous cystadenoma with carcinoma in-situ
Invasive carcinoma arising in mucinous cystadenoma
Intraductal papillary-mucinous
neoplasm with mild dysplasia
Intraductal papillary-mucinous
neoplasm with moderate dysplasia
Intraductal papillary-mucinous neoplasm with carcinoma
in-situ





Subtypes-colloid carcinoma, signet ring cell carcinoma,
adenosquamous carcinoma, undifferentiated (anaplastic)
carcinoma, undifferentiated carcinoma with osteoclastic
gint cells
Pancreatoblastoma
Acinar cell cystadenoma Acinar cell carcinoma
Acinar cell cystadenocarcinoma
Contaminants of Pancreatic EUS FNA
Gastrointestinal (GI) contamination can lead to over
and under interpretation of pancreatic EUS FNAs. Mis-
taking benign GI groups as benign ductal cells can lead
to interpreting an inadequate sample as adequate con-
tributing to a false negative interpretation. Conversely,
reactive atypical GI groups can be mistaken for well-dif-
ferentiated adenocarcinoma leading to a false positive in-
terpretation. Both contaminating epithelia may appear
complex and atypical from folding and dyshesion, or, in
the case of duodenum, presenting as intact villi creating
a diagnostic pitfall for over-interpretation as carcinoma.
These groups of cells are generally distinguishable from
ductal adenocarcinomas as they lack the characteristic
nuclear features of malignancy, and contain goblet cells
and lymphocytes within the epithelium.
Diagnostic Approach to Interpretation
of Pancreatic FNA
When interpreting pancreatic FNA, cytopathologists
use a WHO classification of pancreatic lesions which
broadly divides lesions into solid and cystic17 (Table 1).
Before embarking on interpreting pancreatic FNA cyto-
pathologists should be familiar with the appearances of
the normal, reactive (Figure 1 and 2) and neoplastic con-
ditions, the most common of which are described here.
For a detailed description of these and some rarer condi-
tions, reader should consult one of the standard text-
books18.
Primary pancreatic adenocarcinoma
If the lesion is radiologically solid, differential diagno-
sis includes in over 90% a primary adenocarcinoma. Pan-
creatic adenocarcinoma may be well or poorly differenti-
ated. The main features of malignancy are the following:
overlapping and crowding, nuclear contour irregularity,
gross anisonucleosis and chromatin abnormalities19. Well
differentiated carcinoma may be overlooked and mis-
taken for reactive changes such as found in chronic pan-
creatitis (Figures 3 and 4). Variants of pancreatic adeno-
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Fig 1. FNA pancreas. Normal pancreatic acini are usually ar-
ranged in round, cohesive, complex aggregates with no central
lumen, with cell that have a round, eccentrically placed nucleus,
anisonucleosis, conspicuous nucleolus coarsely granular chro-
matin and abundant and granular cytoplasm.
Fig 2. FNA pancreas. Normal ductal epithelium is usually ar-
ranged in large monolayered sheets with uniformly spaced oval
nuclei, minimal or no overlapping. Cells have small inconspicu-
ous nucleoli, moderate amount of ill-defined cytoplasm and lu-
minal border without visible microvilli.
Fig 3. FNA pancreas. Chronic pancreatitis contains mostly du-
ctal cells, few or no acinar cells, in cohesive monolayered sheets
with very few single cells. Cells have maintained their polarity,
have minimal nucelar overlap, mild anisonucleosis, smooth nu-
clear membranes, rare/normal mitoses and no coagulative necro-
sis. Plasma cells can be seen in autoimmune pancreatitis.
Fig 4. FNA pancreas. Well differentiated adenocarcinoma. Cells
show parachromatin clearing, exaggerated honeycomb pattern,
loss of nuclear polarity and subtle nuclear membrane irregularities.
carcinoma include undifferentiated carcinoma, osteoclast
like giant cell tumour and adenosquamous carcinoma18.
Other »solid« malignancies include lymphoma, sar-
coma, germ cell tumour, metastases, primary endocrine
tumour, solid pseudopapillary neoplasm, acinar cell car-
cinoma and pancreatoblastoma. If the cellular compo-
nents of the FNA material are insufficient for a confident
diagnosis of malignancy, an indeterminate report of »aty-
pical or suspicious« for neoplasm will be issued. In cases
of chronic pancreatitis, autoimmune pancreatitis or nor-
mal pancreatic tissue, a negative report can be issued.
Non-diagnostic material is considered that which, in the
presence of radiological abnormality, does not show any
pathological features or if it is technically inadequate
(blood, polymorphs, crush or drying artefact).
Primary endocrine tumour
Primary endocrine tumours (PET) are uncommon
(0.4/100,000), they have a much better prognosis than
non endocrine tumours. With the advent of EUS FNA
which can target small lesions, the incidence of primary
endocrine tumours (PET) in the FNA is growing. EUS
and EUS-FNA have become the preferred modalities for
localizing and diagnosing PETs, sensitivity and accuracy
rates are between 80–90%20,21.
PETs are usually very vascular tumours and conse-
quently, FNA samples are usually full of blood and inade-
quate for assessment. If adequate, they are hypercellular,
cell monotony/absence of pleomorphism being a notable
feature. Cells are usually arranged as single or in small
clusters with a tendency towards acinar formations. Bran-
ching blood vessels may be present. The individual cells
are round or polygonal, finely granular with a well de-
fined cytoplasm, eccentrically located round to oval nu-
clei (plasmacytoid) and one or two nucleoli. If immuno-
cytochemistry can be performed, this is usually confirma-
tory, particularly chromogranin and synaptophysin. The
latter is more sensitive if less specific and tends to stain a
greater proportion of PETs (Figure 5 and 6). According
to WHO classification, different endocrine tumour types
differ in clinical behaviour and prognosis22 (Table 2).
EUS-FNA findings can predict 5-year survival in pa-
tients with PETs21.
Cystic lesions
Until recently, cysts of the pancreas were thought to
be relatively rare, but with the advances in imaging,
there has been a dramatic increase in the detection of of-
ten asymptomatic cysts23–25. In the past, it has been advo-
cated that all pancreatic cysts be resected due to the un-
certainty in pre-operative diagnosis and the fear of malig-
nant degeneration of a mucinous cyst. However, as we
gain knowledge about the biological behaviour of these
neoplasms and improve our ability to accurately diag-
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TABLE 2
THE WHO CLASSIFICATION OF PANCREATIC ENDOCRINE TUMOURS19A
WHO category Defining feature Clinical behaviour
Well-differentiated endocrine tumour Confined to the pancreas Only rarely show aggressive behavior
Well-differentiated endocrine carcinoma Lymph node or liver metastasis Variable but generally aggressive tumours
Poorly differentiated endocrine carcinoma >10mitosis/10HPF
Small cell carcinoma-like morphology
Extremely aggressive tumour
Fig 5. FNA pancreas. Pancreatic endocrine tumour. Smears are
hypercellular, arranged singly and in small clusters giving a mo-
notonous appearance with absence of pleomorphism. There is a
tendency towards acinar formations. Branching blood vessels may
be present.
Fig 6. FNA pancreas. Pancreatic endocrine tumour. Individual
cells are round or polygonal with fnely granular, well defined cy-
toplasm and eccentrically located round to oval nuclei (plasma-
cytoid).They have one or two nucleoli. Inset: Tumour cells are sy-
naptophysin positive with immunoperoxidase.
nose pancreatic cysts, alternative treatment options to
surgery become available.
Cystic lesions can be non epithelial or epithelial, be-
nign or malignant, of low or high grade malignancy (Ta-
ble 1).
Pseudocyst is the most common non-epithelial cyst. It
is unilocular, contains inflammatory cyst debris, patients
have usually a history of pancreatitis. Cytologically, the
characteristic features include degenerative cyst debris
without thick extracellular mucin, but with acute and
chronic inflammatory cells, histiocytes, and hemosid-
erin-laden macrophages. No cyst lining epithelial cells
should be present, however, contaminating gastric or du-
odenal epithelium and even extracellular mucin may be
present presenting a diagnostic pitfall for the misinter-
pretation of a mucinous cyst (Figure 7). Pseudocysts in-
variably have an elevated amylase level, usually in the
thousands26. An amylase level of <250 U/L virtually ex-
cludes the diagnosis of a pseudocyst. They contain low
CEA, no K-ras or LOH mutations. These are benign cysts
and the management depends on patient’s condition.
Serous cystadenoma (microcystic or glycogen-rich cy-
stadenoma) has characteristic radiological appearances,
is usually poorly cellular, most of the slides being empty
apart from a few flat sheets of bland cuboidal epithelium
with round central to slightly eccentric nuclei and scant
but visible cytoplasm that is homogenous to clear (non
mucin secreting) (Figure 8). They often contain haemo-
siderin laden macrophages. Mucin stains are negative,
fluid has low amylase and CEA levels. A CEA of >200
ng/mL would for all practical purposes exclude a serous
cystadenoma27. Serous cysts are almost always benign.
Mucinous cysts are neoplastic and can be subdivided
into Intraductal papillary mucinous neoplasm (IPMN)
and Mucinous Cystic Neoplasm (MCN). Both lesions
have elevated CEA >200 ng/mL (at MGH) and positive
mucin stains. K-ras mutation or 3 LOH mutations are
supportive of this diagnosis.
Intraductal papillary mucinous neoplasm (IPMN) is a
mucin producing neoplastic cyst that arises from and is
directly connected with the pancreatic ductal system, ei-
ther the main duct and/or side branch duct, and is lined
by typically papillary and variably atypical mucinous epi-
thelium. Most IPMN occur in elderly men and women
with a peak age of close to 65 years and a slight male pre-
dominance. The epithelial lining of IPMN includes gas-
tric-foveolar type, intestinal type, pancreatobiliary type
and oncocytic type. FNA of IPMN produce variable amo-
unts of mucin and cyst lining epithelium, and, as such,
may not accurately reflect the histological grade of the
cyst28–34. A specific diagnosis of IPMN, therefore, is a less
common cytological interpretation than a more general
diagnosis of a neoplastic mucinous cyst that includes
MCN. Air dried smears of thin mucin may produce »fer-
ning«, an indication of its mucinous nature. Mucin stains
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Fig 7. FNA pancreas. Pseudocyst. Numerous macrophages, often
contain aemosiderin as well as cyst debris with blood, proteina-
ceous material and sometimes bile. Variable inflammation and
no cyst lining epithelium present.
Fig 8. FNA pancreas. Serous cystadenoma. Small cuboidal epi-
thelial cells rich in cytoplasmic glycogen on a clean background,
often in monolayered sheets of small flat clusters. Cells have bland
round nuclei, usually central and scant non mucinous cytoplasm.
Fig 9. FNA pancreas. Intraductal papillary mucinous neoplasm.
Background-Abundant thick mucin, mucinous glandular epithe-
lium in sheets, clusters, papillary groups and single. Inset: Mu-
cus secretion in every cell. Cellular atypia can be variable; none-
-adenoma, moderate-borderline and malignant, at least in situ
carcinoma.
(mucicarmine and/or Alcian blue pH 2.5) can help to
identify and distinguish proteinaceous fluid from mucin.
Cytological findings of IPMN with low-grade dysplasia
(adenoma) include variable amounts of mucin, thick,
colloid-like mucin with or without mucinous epithelium,
thin, watery mucin, low cellularity, papillary fragments,
mucinous glandular epithelium with mucin occupying
>1/3rd filling the columnar cytoplasmic compartment,
absence of nuclear atypia and no background necrosis
(Figure 9)18.
IPMN-moderate dysplasia and IPMN-carcinoma are
lined by atypical to malignant appearing glandular epi-
thelium with variable amounts of cytoplasmic mucin. Al-
though malignant IPMN typically have increased overall
cellularity with respect to low-grade neoplasms, not all
carcinomas produce cellular aspirates18. Open chroma-
tin, irregular nuclear membranes and nucleoli, signifi-
cant background inflammation and necrosis supports the
interpretation of an in situ or invasive carcinoma. Com-
plete surgical resection is currently the treatment of
choice, although treatment options are evolving for branch
duct IPMN due to the more often low grade nature of
these neoplasms. Prognosis is directly related to the
presence or absence of an invasive carcinoma35,36.
Mucinous cystic neoplasm (MCN) is a neoplastic mu-
cin producing cyst that, in almost all cases, occurs in a fe-
male, does not communicate with the pancreatic ductal
system, is lined by mucinous epithelial cells with varying
degrees of atypia, and by definition contains subepi-
thelial ovarian type stroma35. On a pure cytological level,
FNA of MCNs for all practical purposes are identical to
those described for IPMN. The subepithelial ovarian-
-type stroma typically is not appreciated on cytology
smears. Unlike IPMN that can have different types of ep-
ithelium lining the cyst, the mucinous lining epithelium
of MCN is generally a single layer of uniform appearing
columnar mucinous epithelium that increases in nuclear
atypia with increasing grade of the neoplasm18. The cyst
lining cells may become attenuated from pressure de-
creasing the mucinous appearance of the cells. Some-
times only cyst debris and foamy histiocytes are seen
and, as such, aspirates may be devoid of identifiable
mucin or epithelial cells causing misdiagnosis as a pseu-
docyst or serous cyst (Figure 10). Biochemical analysis of
the cyst fluid showing CEA levels above 200 ng/mL sup-
port the interpretation of a mucinous cyst and very high
levels of CEA correlate with (but are not diagnostic of
malignancy).
Ancillary Techniques
Although cyst cytology alone is often non-diagnostic,
when evaluated in the context of the clinical history, ra-
diological features and gross cyst fluid observations and
ancillary tests such as special stains for mucin, biochemi-
cal testing for CEA and amylase and increasingly molec-
ular analysis, accuracy can be greatly improved.37–42 An
educated and experienced cytopathologist is critical for
accurate interpretation24,25,33,36–42. The purpose of these
pre-operative investigations is primarily to distinguish
mucinous neoplasms from pseudocysts and serous cysta-
denomas, distinctions that directly affect patient man-
agement decisions43–45.
Molecular analysis of cyst fluid can be carried out
with commercially available kits but it is controversial as
there have been few published reports46–51. As currently
reported malignant cysts require either k-ras gene point
mutation, two or more LOH or high quantity/quality of
DNA with k-ras or LOH mutation present at a high am-
plitude (>75%) suggesting a significant clonal expan-
sion. Mucinous cysts show either k-ras gene point muta-
tion, two or more LOH or high quantity/quality of DNA,
and non-mucinous cysts do not show any of these molec-
ular changes and little, poor quality DNA. A recent study
comparing the molecular classification of cysts into gen-
eral categories of non-mucinous, benign mucinous and
malignant mucinous cysts with the current practice us-
ing clinical, radiological and cyst fluid parameters shows
good concordance52.
In conclusion, FNA pancreas is an evolving discipline,
currently in the forefront of the pre-operative patient
management. A definitive morphological diagnosis can
be made, provided we improve the skills of collection,
preparation and interpretation of pancreatic FNA sam-
ples. In order to maintain and enhance our position in
the management pathway, cytopathologists cannot un-
derestimate the use of ancillary techniques and the value
of the multidisciplinary team approach.
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Fig 10. FNA pancreas. Mucinous Cytic Neoplasm, cytologically
impossible to distinguish from IPMN. There is copious mucin
background and necrotic debris. apillary clusters and sheets of
uniform, columnar cells embedded in mucin with distinct cell
borders, occasional signet ring forms and rarely frankly malig-
nant features. Inset: Tumour cells are Pas diastase positive.
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CITOLO[KA PUNKCIJA GU[TERA^E: DIJAGNOSTI^KI PRISTUP
S A @ E T A K
Citolo{ka punkcija (fine needle aspiration, FNA) je zajedno s tehnikama slikovnog prikaza postala primarnim dijag-
nosti~kim sredstvom ispitivanja cisti~nih i solidnih tvorba gu{tera~e. Napredak u tehnikama slikovnog prikaza pove}ao
je mogu}nost raspoznavanja i ocrtavanja tvorba gu{tera~e, te njihovog ranijeg otkrivanja. Me|utim, kona~no lije~enje
~esto se ne mo`e temeljiti samo na klini~kim i radiolo{kim obilje`jima. Usprkos napretku u tehnikama slikovnog pri-
kaza, mogu}nosti lije~enja ovih bolesnika su ograni~ene, dok je zlo}udna dijagnoza solidnih tvorba jo{ uvijek udru`ena s
visokom stopom smrtnosti. Va`na uloga citopatologa kao ~lana multidisciplinskog tima u prijeoperacijskoj dijagnostici
G. Kocjan: FNA of the Pancreas: a Guide to the Diagnostic Approach, Coll. Antropol. 34 (2010) 2: 749–756
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ilustrira se na primjeru lije~enja bolesnika s neoplasti~nim cistama. Ovo lije~enje se temelji na prijeoperacijskom ra-
zlikovanju nemucinoznih i mucinoznih cista op}enito, te osobito dobro}udnih i zlo}udnih cista. Citolo{ka dijagnoza
dobiva se minimalno invazivnom tehnikom, vo|enom kompjutoriziranom tomografijom, ultrazvukom ili endoskopskim
ultrazvukom. Citolo{ka punkcija pod kontrolom endoskopskog ultrazvuka (EUS FNA) razvija se u dijagnosti~ku me-
todu izbora zahvaljuju}i mogu}nosti da se to~nije utvrdi stadij bolesnika u samo jednom postupku pomo}u EUS.
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